Navigation Links
Beike Biotechnology Study Suggests Adult Stem Cells Show Promise,for Peripheral Vascular Disease

cers improved or healed in 46 (86.8%) of the 53 patients, while 25 of the 48 (47.9%) patients with limb gangrene remained steady or improved. Angiography (an X-ray) before treatment, and at 12 weeks after treatment, was performed in 10 of the patients and showed formation of new collateral vessels.

The patients had no severe adverse effects or complications related to cell transplantation.

"These preliminary results, while encouraging, must be further researched in future controlled studies and reinforced by separate studies by other laboratories," said Yang Xiao Feng, Director of the Stem Cell Program for Vascular Diseases at Shenyang 463 Hospital.

The study followed previous studies done in the laboratory and pre- clinical work done in rabbits.

"There is evidence demonstrating significant improvement in the quality of life of patients receiving the treatment, including formation of new collateral vessels," said Sean Hu, Chairman of Beike Biotechnology group. "We are now working to collaborate with institutions in the U.S. to further substantiate this and other studies including those we are doing for neurological diseases using umbilical cord stem cells."

In 2006, Beike Biotechnology completed two studies involving eight patients with ALS. Two papers were published in the Journal of Zhenghou University of Medical Science. The first observed the effect of transplantation of umbilical cord blood mesenchymal stem cells (UCB-MSCs) on glutamate (Glu) levels in plasma and CSF of amyotrophic lateral sclerosis patients and the second observed the effect of umbilical cord blood mesenchymal stem cell transplantation on nervous system function of ALS patients.

About Shenzhen Biotech Co., Ltd.

Beike is a leading biotechnology company founded with capital from Beijing University, Hong Kong University of Science and Technology and Shenzhen City Hall. It is also supported with funds from the China State National Fund. The research
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Prana Biotechnology Presents New Key Findings on PBT2
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
6. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results

Post Your Comments:
(Date:11/30/2009)...if., Nov. 30 StemCyte, Inc. conclu...eement with Academia Sinica, the National Laborato...Intellectual Property (IP) related to the treatmen...and IP was pioneered by a team led by Professor Jo...rofessor Lin is currently the exclusive collaborat...
(Date:11/30/2009)...LLS, Mich., Nov. 30 eHealthSource....ted exclusively to products approved for Flexible ...A) claims. The site is also the first to exclusiv...s, saving shoppers up to 75 percent on everyday he...wo common healthcare headaches - high costs and co...
(Date:11/30/2009)... Italy, November 30 Health Robotic... development plans and product specifications,for ...d Parenteral,Nutrition", a new key component of it...t Las Vegas, ASHP (Booth # 114). , "I loo...o the,TPNstation,s blueprints and to find out if T...
Breaking Medicine Technology:StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 2StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 3eHealthSource.com Launches Online Shopping Site Dedicated to Over-the Counter Medications Approved for FSA/HSA Claims 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 2Health Robotics to Unveil TPNstation(TM) at the American Society of Health-System Pharmacists on December 7th 3China Kangtai Cactus Biotech to Attend Rodman 26 Renshaw Conference and Meet with Investors in September 55140 1China Kangtai Cactus Biotech to Attend Rodman 26 Renshaw Conference and Meet with Investors in September 55140 2China Kangtai Cactus Biotech to Attend Rodman 26 Renshaw Conference and Meet with Investors in September 55140 3MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging 13666 1MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging 13666 2MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging 13666 3MEDRAD Partners with the University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging 13666 4Obama Named the Most Powerful Person in Healthcare 55134 1Obama Named the Most Powerful Person in Healthcare 55134 2
...tes Presented at the,67th Annual Scientific Sessio..., June 25, 2007 /PRNewswire/ -- DiObex, Inc., a,pr...the development,of therapeutics to treat metabolic... line data of its phase 2a study of DIO-902, a,fir...e treatment of,type 2 diabetes. , Results of the t...
...- Neurogen,Corporation (Nasdaq: NRGN) today announ...g, Phase 2b clinical trials in chronic,insomnia pa...nt,NG2-73, an alpha-3 preferring GABA(A) partial ...h trial to determine the best,profile for rapidity...he night without residual sedation the next day., ...
Other Medicine Technology:DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 2DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 2Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 3Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 4Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 5Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 6Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 7Neurogen Announces Positive Results for Proprietary Insomnia Drug,in Two Chronic Insomnia Clinical Trials 8
(Date:11/30/2009)... , SILVER SPRING, Md., Nov. 30 /PRNewsw...se consumers a bronzed body year-round, but the ul...serious health risks. ,, (Logo: http://www.ne...Although some people think that a tan gives them a..." says Sharon Miller, M.S.E.E., a Food and Drug Ad...
(Date:11/30/2009)... , CHICAGO, Nov. 30 Physicians...reported today on results of a study demonstrating...CT angiography (cCTA) by Rcadia,s COR Analyzer Sys... artery stenosis in hospital emergency department ... automated system to enhance the use of cCTA has p...
(Date:11/30/2009)... University of Navarra Hospital has launched a ser...cacy of an immunotherapy treatment. This approach ...produced from healthy and tumour cells from the pa...astomas, one of the most aggressive and frequent m...to participating patients combined with the standa...
(Date:11/30/2009)... Peter J. Rappa, MD, explores ...body in his new book "Healing Heart to Soul: ... Life" (Brown Books 2009). , ...Experiencing and refusing to let go of negative em...s, can weigh heavy on our shoulders. Oftentimes, t...
(Date:11/30/2009)... , NEW YORK, Nov. 30 Re...h report is available in its catalogue: ,, Gen...rtunities ,, http://www.reportlinker.com/p016...pportunities.html ,, Gene therapy promises to...e. Although no significant achievements for curing...
Breaking Medicine News(10 mins):Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health 2Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 2Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 3Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 4Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 5
...nts , , MONDAY, Jan. 7 (HealthDay News) --...sunlight, some foods and supplements -- are assoc...blems such as heart attack and stroke, U.S. resear...sachusetts city. , The research team found that th...
...r Integrative Health Solutions for Te...Jan. 7 Gaiam, Inc., the,leading distributor of sp...nt of the fitness and wellness market, today annou... - obesity,type 2 diabetes, back pain, high blood ...
...ga AB, a subsidiary of Cambrex Corporation (NYSE: ... a purchase agreement for all of the stock,of ProS...ingredients,("API") research and development compa... a spin off from Tallinn University,of Technology,...
...r prescriptions, kept exam dates, study finds , ...buying contact lenses online may save time in the ...oper eye care, new research shows. , Time saved ...ale clubs or optical chains were also less likely ...
... at any given time, almost 10 percent of the emerg...the United States miss work because of injuries an...examining how common these injuries are and tracki...ponders will suffer an injury or illness forcing t...
...ARRISBURG, Pa., Jan. 7 Nutrition has moved up on ...cent) consider the nutritional,content of foods th...did,two to three years ago, says a new survey from...en,s nutrition., However, the battle between nutr...
Other Medicine News:Health News:Low Vitamin D Linked to Heart Risk 2Health News:Low Vitamin D Linked to Heart Risk 3Health News:Gaiam Inc., The Leader in Innovative Lifestyle Solutions, Announces New DVD Series Created with Mayo Clinic 2Health News:Gaiam Inc., The Leader in Innovative Lifestyle Solutions, Announces New DVD Series Created with Mayo Clinic 3Health News:Cambrex Signs Agreement To Acquire ProSyntest AS 2Health News:Eye Care Lacking in Many Who Buy Contact Lenses Online 2Health News:Emergency responders at high risk to miss work because of injuries 2Health News:Emergency responders at high risk to miss work because of injuries 3Health News:Nutrition Moves Up on Mom's Purchasing Agenda 2Health News:Nutrition Moves Up on Mom's Purchasing Agenda 3
...y EX.P.R.T. Release Technology essentially elimina...ent shortening,, Unique anatomically design...urcation,, 0.014 Rapid Exchange catheter wi...ic tip,, Radiopaque marker on catheter clea...
EZ Steer Bi-Directional Catheter
... whole blood assayed hematology control, offers co...ifferential available with the Coulter GENS, STKS,...-vial stability, 105-day closed-vial stability and...4.0ml pierceable cap vial is compatible with all c...
Pilot® Thoracolumbar Pedicle Screw System
Medicine Products: